Currently Viewing:
Newsroom
Currently Reading
What We're Reading: UnitedHealthcare Prefers Biosimilars; Migraine Coverage; Prostate Cancer Disparity
October 18, 2018 – AJMC Staff
Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial
October 17, 2018 – Samantha DiGrande
Express Scripts Launching Value-Based Migraine Program
October 17, 2018 – Jaime Rosenberg
What We're Reading: Promoting Pediatric Cancer Research; Mystery Paralysis; Cost of Being Sick
October 17, 2018 – AJMC Staff
Three Genetic Types Drive Higher Prevalence of MM in African Americans
October 14, 2018 – Laura Joszt
ACOs Had No Significant Impact on Spending for Patients With Cancer
October 14, 2018 – Laura Joszt
Know the Risk: 5 Breast Cancer Risk Factors
October 12, 2018 – Samantha DiGrande
Inhaler Effective for Treating Migraine Attacks, According to Pilot Study
October 12, 2018 – Alison Rodriguez
The US Oncology Network Announces Highly Positive MIPS Results for 2017
October 12, 2018 – Laura Joszt

What We're Reading: UnitedHealthcare Prefers Biosimilars; Migraine Coverage; Prostate Cancer Disparity

AJMC Staff
UnitedHealthcare has announced it is listing 3 biosimilars as preferred drugs; Express Scripts has decided it will cover Eli Lilly’s and Amgen’s migraine drugs and will not cover Teva Pharmaceutical's drug; black men are more likely to get and die from prostate cancer compared with white men, but they are underrepresented in prostate cancer research because of a general distrust of the healthcare system.

UnitedHealthcare Prefers Biosimilars in MA Plans

As part of CMS’ policy change that will allow Medicare Advantage plans to implement step therapy, UnitedHealthcare has announced it is listing 3 biosimilars as preferred drugs, according to The Center for Biosimilars®, a site from The American Journal of Managed Care®. Infliximab biosimilars Inflextra and Renflexis will be preferred over the reference, Remicade, and biosimilar epoetin alfa, sold as Retacrit, will be a preferred drug.

 

Express Scripts Will Cover 2 of 3 New Migraine Drugs

After price negotiations with Eli Lilly, Amgen, and Teva Pharmaceutical, Express Scripts has decided it will only cover Eli Lilly’s and Amgen’s migraine drugs. According to Reuters, the pharmacy benefit manager will limit the use of the migraine drugs to patients who are most likely to benefit. The 3 treatments work similarly, had similar success in reducing migraine frequency, and all have a list price of $575 a month. Amgen’s Aimovig was approved first in May 2018 and is listed as Express Scripts’ preferred treatment after patients try 2 older preventive therapies and triptan.

 

Black Men Underrepresented in Prostate Cancer Research

Despite the fact that black men are more likely to get and die from prostate cancer than white men, they are underrepresented in research because of distrust. NPR reported that focus groups of black men were unfamiliar with and less likely to pursue genomic testing, which could identify personalized approaches to monitoring and treating cancer. In general, the focus groups found a distrust in the healthcare system, stemming from ways African Americans have been treated by the medical system in the past.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up